GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

HR17031

Company
Jiangsu HengRui Medicine Co., Ltd.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT05031871

    Pharmacokinetics of HR17031 Injection in Healthy Subjects

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 24 participants Est. completion 2021-11-19 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT05151705

    A Trial of HR17031 Injection With Hepatic Insufficiency

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 24 participants Est. completion 2022-06-30 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT05292495

    A Trial of HR17031 Injection With Renal Insufficiency

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 24 participants Est. completion 2024-04-10 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT05333835

    A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 455 participants Est. completion 2024-03-30 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06086912

    A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 24 participants Est. completion 2023-12-12 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06871761

    A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 393 participants Est. completion 2025-05-13 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06881264

    A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 401 participants Est. completion 2025-09-19 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.